Conditioning, Donor, and Genotype: Hematopoietic Cell Transplantation for Malignant Infantile Osteopetrosis in 2026 [0.03%]
调理方案、供者选择和基因型对恶性婴儿骨髓增生异常综合征造血干细胞移植的影响（2026年）
Polina Stepensky
Polina Stepensky
Moving Homes [0.03%]
搬家
Katayoun Rezvani
Katayoun Rezvani
Cis-targeted IL-2 mutein to augment the anti-tumor activity of engineered T cells [0.03%]
工程化T细胞增强抗肿瘤活性的顺式靶向白细胞介素-2突变体
Sara Sleiman,Nathan D Mathewson,Tyler Hansen et al.
Sara Sleiman et al.
Adoptively transferred T cells require cytokine stimulation, which is achieved using lymphodepleting chemotherapy with or without administration of exogenous interleukin 2 (IL-2). Lymphodepleting chemotherapy (LDC) is associated with cytope...
Reduced-Dose PTCy Plus Post-Engraftment Low-Dose ATG for GVHD Prophylaxis in Haploidentical PBSC Transplantation [0.03%]
减量PTCy联合后移低剂量抗人T细胞免疫球蛋白预防单倍型相合外周血干细胞移植后移植物抗宿主病
Xiaojuan An,Yu Tao,Yun Ma et al.
Xiaojuan An et al.
Background: Post-transplant cyclophosphamide (PTCy) combined with antithymocyte globulin (ATG) is increasingly used for graft-versus-host disease (GVHD) prophylaxis after haploidentical hematopoietic cell transplantation ...
Nosocomial Respiratory Virus Infections in Hematologic Malignancies: Risk Factors for Progression to Lower Respiratory Tract Infection [0.03%]
血液系统恶性肿瘤中的院内呼吸道病毒感染进展为下呼吸道感染的危险因素分析
Keon Oh,Sung-Yeon Cho,Dong-Gun Lee et al.
Keon Oh et al.
Background: Respiratory virus (RV) infections cause significant morbidity in patients with hematologic malignancies (HM) and hematopoietic stem cell transplant (HCT) recipients. However, predictors of progression from upp...
CAR-based cellular therapies for autoimmune diseases: immune reset, clinical evidence, and translational boundaries [0.03%]
基于CAR的细胞疗法治疗自身免疫疾病：重置免疫系统、临床证据和转化边界
Miao Huang,Renjie Huang,Dongyan Wang
Miao Huang
CAR-based cellular therapy is emerging as a time-limited strategy for severe autoimmune disease, but its clinical value depends on more than early response. We conducted a structured narrative review with a targeted update of PubMed/MEDLINE...
Real-World Analysis of Post-Transplant Cyclophosphamide on Allogeneic HCT Landscape [0.03%]
苯达莫司汀和后移植环磷酰胺对allo-HCT受者移植物抗宿主病和复发风险的影响：CIBMTR注册表的一项研究分析
Tara Sebastian,Tingyu Wang,Ioannis E Louloudis et al.
Tara Sebastian et al.
Eligibility Matched Benchmarking of Second-Line Anti-CD19 CAR-T and Glofit-GemOx (STARGLO) Outcomes in Large B-Cell Lymphoma [0.03%]
大B细胞淋巴瘤二线抗CD19 CAR-T与Glofit-mab-GemOx（STARGLO）结局的对照分析
Gil Fridberg,Odelia Amit,Muhammad Ganayem et al.
Gil Fridberg et al.
Clinical Impact of Discordant Minimal Residual Disease Assessment in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation [0.03%]
allo-HSCT后白血病细胞检测不一致对成人急性淋巴细胞白血病患者预后的临床影响
Jae-Ho Yoon,Jin Jung,Seok Lee et al.
Jae-Ho Yoon et al.
Background: Measurable residual disease (MRD) is a key prognostic marker in adult B-cell precursor acute lymphoblastic leukemia (B-ALL), yet inter-assay discordance may complicate MRD-guided decisions, particularly around...
Comment on"Alemtuzumab, Fludarabine, Melphalan, and Thiotepa Conditioning for Transplantation in Inborn Errors of Immunity" [0.03%]
关于“用于先天性免疫缺陷移植的阿仑单抗、氟达拉滨、美法仑和噻替派预处理”一文的述评
Samir Iddir,Brahim Lounis,Zakia Batoul Benlahreche et al.
Samir Iddir et al.